Of note, Kang et al. presented novel data suggesting a beneficial role for the FFA2 (GPR43) agonist, 4-chloro-α-(1-methylethyl)-N-2-thiazoylylbenzeneacetanilide (4-CMTB), in a mouse model of 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis. Here, FFAR2 is linked to atopic eczema.